Product Description: Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3(6):e119.